135 related articles for article (PubMed ID: 12439332)
1. E7070: a novel synthetic sulfonamide targeting the cell cycle progression for the treatment of cancer.
Van Kesteren C; Beijnen JH; Schellens JH
Anticancer Drugs; 2002 Nov; 13(10):989-97. PubMed ID: 12439332
[TBL] [Abstract][Full Text] [Related]
2. Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-early clinical studies group (ECSG).
Punt CJ; Fumoleau P; van de Walle B; Faber MN; Ravic M; Campone M
Ann Oncol; 2001 Sep; 12(9):1289-93. PubMed ID: 11697842
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells.
Fukuoka K; Usuda J; Iwamoto Y; Fukumoto H; Nakamura T; Yoneda T; Narita N; Saijo N; Nishio K
Invest New Drugs; 2001; 19(3):219-27. PubMed ID: 11561678
[TBL] [Abstract][Full Text] [Related]
4. E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo.
Ozawa Y; Sugi NH; Nagasu T; Owa T; Watanabe T; Koyanagi N; Yoshino H; Kitoh K; Yoshimatsu K
Eur J Cancer; 2001 Nov; 37(17):2275-82. PubMed ID: 11677118
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle.
Owa T; Yoshino H; Okauchi T; Yoshimatsu K; Ozawa Y; Sugi NH; Nagasu T; Koyanagi N; Kitoh K
J Med Chem; 1999 Sep; 42(19):3789-99. PubMed ID: 10508428
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG).
Terret C; Zanetta S; Roché H; Schellens JH; Faber MN; Wanders J; Ravic M; Droz JP;
Eur J Cancer; 2003 May; 39(8):1097-104. PubMed ID: 12736109
[TBL] [Abstract][Full Text] [Related]
7. New analogues of the anticancer E7070: synthesis and pharmacology.
Laconde G; Pommery N; Depreux P; Berthelot P; Hénichart JP
J Enzyme Inhib Med Chem; 2003 Apr; 18(2):89-94. PubMed ID: 12943191
[TBL] [Abstract][Full Text] [Related]
8. A phase II clinical and pharmacodynamic study of E7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell cycle inhibitor.
Haddad RI; Weinstein LJ; Wieczorek TJ; Bhattacharya N; Raftopoulos H; Oster MW; Zhang X; Latham VM; Costello R; Faucher J; DeRosa C; Yule M; Miller LP; Loda M; Posner MR; Shapiro GI
Clin Cancer Res; 2004 Jul; 10(14):4680-7. PubMed ID: 15269140
[TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer.
Raymond E; ten Bokkel Huinink WW; Taïeb J; Beijnen JH; Faivre S; Wanders J; Ravic M; Fumoleau P; Armand JP; Schellens JH;
J Clin Oncol; 2002 Aug; 20(16):3508-21. PubMed ID: 12177112
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors.
Dittrich C; Dumez H; Calvert H; Hanauske A; Faber M; Wanders J; Yule M; Ravic M; Fumoleau P
Clin Cancer Res; 2003 Nov; 9(14):5195-204. PubMed ID: 14613999
[TBL] [Abstract][Full Text] [Related]
11. Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days.
Yamada Y; Yamamoto N; Shimoyama T; Horiike A; Fujisaka Y; Takayama K; Sakamoto T; Nishioka Y; Yasuda S; Tamura T
Cancer Sci; 2005 Oct; 96(10):721-8. PubMed ID: 16232205
[TBL] [Abstract][Full Text] [Related]
12. Cell cycle regulation in the G1 phase: a promising target for the development of new chemotherapeutic anticancer agents.
Owa T; Yoshino H; Yoshimatsu K; Nagasu T
Curr Med Chem; 2001 Oct; 8(12):1487-503. PubMed ID: 11562278
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation.
Van Kesteren Ch; Mathôt RA; Raymond E; Armand JP; Dittrich Ch; Dumez H; Roché H; Droz JP; Punt C; Ravic M; Wanders J; Beijnen JH; Fumoleau P; Schellens JH;
J Clin Oncol; 2002 Oct; 20(19):4065-73. PubMed ID: 12351604
[TBL] [Abstract][Full Text] [Related]
14. An excretion balance and pharmacokinetic study of the novel anticancer agent E7070 in cancer patients.
van sen Bongard HJ; Pluim D; Rosing H; Nan-Offeringa L; Schot M; Ravic M; Schellens JH; Beijnen JH
Anticancer Drugs; 2002 Sep; 13(8):807-14. PubMed ID: 12394264
[TBL] [Abstract][Full Text] [Related]
15. Indisulam: an anticancer sulfonamide in clinical development.
Supuran CT
Expert Opin Investig Drugs; 2003 Feb; 12(2):283-7. PubMed ID: 12556221
[TBL] [Abstract][Full Text] [Related]
16. Profiling novel sulfonamide antitumor agents with cell-based phenotypic screens and array-based gene expression analysis.
Yokoi A; Kuromitsu J; Kawai T; Nagasu T; Sugi NH; Yoshimatsu K; Yoshino H; Owa T
Mol Cancer Ther; 2002 Feb; 1(4):275-86. PubMed ID: 12467223
[TBL] [Abstract][Full Text] [Related]
17. Anticancer agent E7070 inhibits amino acid and uracil transport in fission yeast.
Tsukahara K; Watanabe T; Hata-Sugi N; Yoshimatsu K; Okayama H; Nagasu T
Mol Pharmacol; 2001 Dec; 60(6):1254-9. PubMed ID: 11723232
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of N-(7-indolyl)-3-pyridinesulfonamide derivatives as potent antitumor agents.
Owa T; Yoshino H; Okauchi T; Okabe T; Ozawa Y; Hata Sugi N; Yoshimatsu K; Nagasu T; Koyanagi N; Kitoh K
Bioorg Med Chem Lett; 2002 Aug; 12(16):2097-100. PubMed ID: 12127512
[TBL] [Abstract][Full Text] [Related]
19. In vitro pharmacokinetic study of the novel anticancer agent E7070: red blood cell and plasma protein binding in human blood.
Bongard HJ; Pluim D; Waardenburg RC; Ravic M; Beijnen JH; Schellens JH
Anticancer Drugs; 2003 Jul; 14(6):405-10. PubMed ID: 12853880
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic drug-drug interaction of the novel anticancer agent E7070 and acenocoumarol.
van den Bongard HJ; Sparidans RW; Critchley DJ; Beijnen JH; Schellens JH
Invest New Drugs; 2004 Apr; 22(2):151-8. PubMed ID: 14739663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
